OHSU

IRB #

IRB00010264

Title

Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)

Principal Investigator

Deniz Erten-Lyons

Study Purpose

The purpose of this study is to test whether an investigational drug called solanezumab, which is given by infusion through a vein, can slow the progression of memory problems associated with Alzheimer's disease.

Medical Condition(s)

Alzheimer's disease

Eligibility Criteria

In good general health, 65-85 years old, at risk for memory decline due to Alzheimer's.

Age Range

65 - 85

Healthy Volunteers Needed

Yes

Duration of Participation

168 weeks

Minors Included

No

Contact

Allison Bianchi- 503-494-7615

Sponsor

National Institute on Aging, Alzheimer's Disease Cooperative Studies, Eli Lilly and Co.

Recruitment End

12/01/2016

Compensation Provided

Yes

Compensation

$25.00 for each completed clinical study visit and $25.00 for each completed infusion visit.


Go Back